/NARI
NARI Stock - Inari Medical, Inc.
Healthcare|Medical - DevicesNASDAQ
$79.97+0.00%
+$0.00 (+0.00%) • Feb 18
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).25
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-12.5%upside
Target: $69.97
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NARI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$79.17 – $80.77
TARGET (TP)$69.94
STOP LOSS$73.57
RISK/REWARD1:-1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.03
52W High$79.99
52W Low$36.73
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $493.63M | $383.47M | $276.98M | $139.67M | $51.13M |
| Gross Profit | $434.56M | $338.96M | $252.23M | $126.56M | $45.22M |
| Gross Margin | 88.0% | 88.4% | 91.1% | 90.6% | 88.4% |
| Operating Income | $-14,032,000 | $-28,099,000 | $6.67M | $18.42M | $801,494 |
| Net Income | $-1,636,000 | $-29,267,000 | $9.84M | $13.79M | $-1,907,118 |
| Net Margin | -0.3% | -7.6% | 3.6% | 9.9% | -3.7% |
| EPS | $-0.03 | $-0.55 | $0.20 | $0.43 | $-0.04 |
Company Overview
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
64%
Hold / Neutral
4
36%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
7 Bullish4 Neutral/Bearish
Price Targets
$73
Average Target
↓ 8.4% Downside
Now
$47
Low
$73
Average
$100
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2024 | Oppenheimer | Initiation | Outperform | $75 |
| September 18th 2024 | Stifel | Initiation | Hold | $50 |
| September 3rd 2024 | Leerink Partners | Initiation | Market Perform | $47 |
| August 9th 2024 | Deutsche Bank | Initiation | Buy | $68 |
| July 25th 2024 | William Blair | Initiation | Outperform | - |
| July 18th 2024 | Needham | Downgrade | Hold | - |
| February 29th 2024 | Piper Sandler | Downgrade | Neutral | $55← $85 |
| January 23rd 2024 | Needham | Initiation | Buy | $72 |
| July 19th 2023 | Robert W. Baird | Initiation | Outperform | $79 |
| October 12th 2022 | Jefferies | Initiation | Buy | $88 |
| September 29th 2022 | Berenberg | Initiation | Buy | $85 |
| September 13th 2022 | Truist | Initiation | Hold | $87 |
| June 21st 2022 | Piper Sandler | Initiation | Overweight | $100 |
Earnings History & Surprises
NARIBeat Rate
74%
Last 19 quarters
Avg Surprise
+238.8%
EPS vs Estimate
Beats / Misses
14/5
Last 12 quarters
Latest EPS
$0.05
Q1 2025
EPS Surprise History
Q2 23
+82.6%
$-0.04vs$-0.23
Q3 23
+130.8%
$0.04vs$-0.13
Q4 23
+1026.1%
$0.05vs$0.00
Q1 24
+1433.3%
$0.05vs$-0.00
Q2 24
-136.4%
$-0.26vs$-0.11
Q3 24
-156.2%
$-0.41vs$-0.16
Q4 24
-8.3%
$-0.13vs$-0.12
Q1 25
+600.0%
$0.05vs$-0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Feb 26, 2025 | $-0.01 | $0.05 | +600.0% | ✓ BEAT |
Q4 2024 | Oct 28, 2024 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q3 2024 | Jul 30, 2024 | $-0.16 | $-0.41 | -156.2% | ✗ MISS |
Q2 2024 | Apr 30, 2024 | $-0.11 | $-0.26 | -136.4% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.00 | $0.05 | +1433.3% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.00 | $0.05 | +1026.1% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.13 | $0.04 | +130.8% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.23 | $-0.04 | +82.6% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.17 | $-0.11 | +35.3% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.24 | $-0.19 | +20.8% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.03 | $0.02 | -23.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $0.08 | $0.07 | -12.5% | ✗ MISS |
Q2 2021 | May 11, 2021 | $0.05 | $0.13 | +160.0% | ✓ BEAT |
Q1 2021 | Mar 9, 2021 | $0.01 | $0.13 | +875.2% | ✓ BEAT |
Q4 2020 | Nov 12, 2020 | $0.02 | $0.12 | +415.7% | ✓ BEAT |
Q3 2020 | Aug 11, 2020 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q2 2020 | May 26, 2020 | — | $0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NARI
What is NARI's current stock price?
Inari Medical, Inc. (NARI) is currently trading at $79.97 per share. The stock has moved +0.00% today.
What is the analyst price target for NARI?
The average analyst price target for NARI is $69.94, based on 1 analyst.
What sector is Inari Medical, Inc. in?
Inari Medical, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is NARI's market cap?
Inari Medical, Inc. has a market capitalization of $4.68 billion, making it a mid-cap company.
Does NARI pay dividends?
No, Inari Medical, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALPN
Alpine Immune Sciences, Inc.
$64.97
Mkt Cap: $4.5B
AXNX
Axonics, Inc.
$70.98
Mkt Cap: $3.6B
CBAY
CymaBay Therapeutics, Inc.
$32.48
Mkt Cap: $3.7B
ISEE
IVERIC bio, Inc.
$39.95
Mkt Cap: $5.5B
LHCG
LHC Group, Inc.
$169.81
Mkt Cap: $5.3B
MRTX
Mirati Therapeutics, Inc.
$58.70
Mkt Cap: $4.1B
OPT
Opthea Limited
$3.41
Mkt Cap: $0.5B
RCM
R1 RCM Inc.
$14.31
Mkt Cap: $6.0B
RYZB
RayzeBio, Inc. Common Stock
$62.49
Mkt Cap: $3.8B
SYNH
Syneos Health, Inc.
$42.98
Mkt Cap: $4.5B
Explore stocks similar to NARI for comparison